The editors of this paper frequently get asked why they publish so many letters that tilt leftward in a state where so many voters tilt rightward. The obvious answer, straightforwardly given, is that ...

Apple has rolled out iOS 26.3.1, a focused update aimed at refining the user experience. While it doesn’t introduce major new features, this release emphasizes compatibility improvements, bug fixes, ...

Apple’s new Studio Display has long been rumored to feature an A19 chip—the same one that debuted in iPhone 17 last fall. However, as discovered by MacRumors in new Studio Display firmware released ...

President Trump said in June he would decide "within the next two weeks" whether to strike Iran. He made the decision two days later. On Thursday, he gave Tehran another deadline, saying the Islamic ...

A couple of days ago, I compiled a detailed roundup of all the products we’re expecting from Apple at the upcoming media “experience” on March 4, 2026. In the story, we discussed new devices like new ...

You can’t tell now, but I am writing this column in longhand. I’m on a tropical island (don’t hate me) without access to a computer screen (ditto) and composing a column this way is an enlightening — ...

MILAN — At first, the world’s top pairs skaters appeared to have cleansed the bad spirits of a men’s competition that ended so sloppily some could only conjure the excuse of a Friday the 13th curse.

Vanderbilt basketball has surpassed its 2024-25 win total with a few weeks left to go in the season and has done it while demonstrating what an extra year of Mark Byington's tenure can do for it.

Qatar announced two new 10-year golden visa pathways aimed at entrepreneurs and executives, without requiring investment for long-term residency. Here’s what to know. If you're looking to start or ...

EXCLUSIVE: Disney Entertainment Television has chosen its participants for the 2025-26 Directing and Writing Programs, talent development initiatives which connect emerging writers and directors with ...

Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...